Survey on Japanese emergency physicians' awareness of advanced mechanical circulatory support upgrade therapy for patients with out-of-hospital cardiac arrest receiving extracorporeal cardiopulmonary resuscitation.
{"title":"Survey on Japanese emergency physicians' awareness of advanced mechanical circulatory support upgrade therapy for patients with out-of-hospital cardiac arrest receiving extracorporeal cardiopulmonary resuscitation.","authors":"Tasuku Hada, Toru Hifumi, Shutaro Isokawa, Yasumasa Tsukamoto, Norihide Fukushima, Norio Otani","doi":"10.1007/s10047-025-01502-1","DOIUrl":null,"url":null,"abstract":"<p><p>Destination therapy (DT) using an implantable left ventricular assist device (i-LVAD) in Japan has expanded treatment options for patients with out-of-hospital cardiac arrest (OHCA) receiving extracorporeal cardiopulmonary resuscitation (ECPR). However, achieving hemodynamic stabilization and improved peripheral organ perfusion is essential. In patients with OHCA, percutaneous mechanical circulatory support (MCS) devices may be inadequate in some cases, necessitating surgical MCS. Despite the growing importance of MCS upgrading, awareness among Japanese emergency physicians remains unclear. We aimed to assess awareness of advanced MCS upgrading strategies in refractory patients after ECPR. A nationwide survey of 293 emergency and critical care centers in Japan assessed awareness of i-LVAD therapy after ECPR. The questionnaire collected data on demographics, LVAD strategy recognition, MCS upgrade practices, and barriers. Of 90 facilities (31%) that responded, 87 (30%) consented to using their responses in the analysis. Awareness of DT was 59.8%. Notably, 66.7% and 70.1% of the respondents recognized that MCS upgrading could lead to i-LVAD treatment and heart transplantation, respectively. The major barrier to MCS upgrade therapy was the facility's inability to implement it. DT awareness was similar between IMPELLA-registered and non-registered facilities, but i-LVAD indication recognition was higher in IMPELLA-registered facilities (78.0% vs. 51.4%, P = 0.009). The low survey response rate suggests limited MCS upgrade awareness among Japanese emergency physicians. Although facilities recognize pathways to i-LVAD and transplantation, barriers to their implementation persist. IMPELLA-registered facilities showed higher i-LVAD indication recognition, reflecting their accessibility to LV unloading devices and connections with backup hospitals.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Artificial Organs","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s10047-025-01502-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Destination therapy (DT) using an implantable left ventricular assist device (i-LVAD) in Japan has expanded treatment options for patients with out-of-hospital cardiac arrest (OHCA) receiving extracorporeal cardiopulmonary resuscitation (ECPR). However, achieving hemodynamic stabilization and improved peripheral organ perfusion is essential. In patients with OHCA, percutaneous mechanical circulatory support (MCS) devices may be inadequate in some cases, necessitating surgical MCS. Despite the growing importance of MCS upgrading, awareness among Japanese emergency physicians remains unclear. We aimed to assess awareness of advanced MCS upgrading strategies in refractory patients after ECPR. A nationwide survey of 293 emergency and critical care centers in Japan assessed awareness of i-LVAD therapy after ECPR. The questionnaire collected data on demographics, LVAD strategy recognition, MCS upgrade practices, and barriers. Of 90 facilities (31%) that responded, 87 (30%) consented to using their responses in the analysis. Awareness of DT was 59.8%. Notably, 66.7% and 70.1% of the respondents recognized that MCS upgrading could lead to i-LVAD treatment and heart transplantation, respectively. The major barrier to MCS upgrade therapy was the facility's inability to implement it. DT awareness was similar between IMPELLA-registered and non-registered facilities, but i-LVAD indication recognition was higher in IMPELLA-registered facilities (78.0% vs. 51.4%, P = 0.009). The low survey response rate suggests limited MCS upgrade awareness among Japanese emergency physicians. Although facilities recognize pathways to i-LVAD and transplantation, barriers to their implementation persist. IMPELLA-registered facilities showed higher i-LVAD indication recognition, reflecting their accessibility to LV unloading devices and connections with backup hospitals.
在日本,使用植入式左心室辅助装置(i-LVAD)的目的治疗(DT)扩大了接受体外心肺复苏(ECPR)的院外心脏骤停(OHCA)患者的治疗选择。然而,实现血流动力学稳定和周围器官灌注改善是必不可少的。在OHCA患者中,经皮机械循环支持(MCS)装置在某些情况下可能不够,需要手术MCS。尽管MCS升级的重要性日益增加,但日本急诊医生的意识仍不清楚。我们的目的是评估ECPR后难治性患者对先进MCS升级策略的认识。一项对日本293个急诊和重症护理中心的全国性调查评估了ECPR后i-LVAD治疗的认识。问卷收集了人口统计、LVAD策略识别、MCS升级实践和障碍方面的数据。在回应的90家机构(31%)中,87家(30%)同意在分析中使用他们的回答。DT知晓率为59.8%。值得注意的是,66.7%和70.1%的受访者分别认识到MCS升级可能导致i-LVAD治疗和心脏移植。MCS升级治疗的主要障碍是医院无法实施。在impella注册和未注册的设施之间,DT认知度相似,但在impella注册的设施中,i-LVAD适应症认知度更高(78.0% vs. 51.4%, P = 0.009)。较低的调查回复率表明,日本急诊医生对MCS升级的认识有限。虽然医院已经识别了i-LVAD和移植的途径,但实施的障碍仍然存在。impella注册的医院对i-LVAD适应症的认可度较高,这反映了它们对LV卸载设备的可及性以及与后备医院的联系。
期刊介绍:
The aim of the Journal of Artificial Organs is to introduce to colleagues worldwide a broad spectrum of important new achievements in the field of artificial organs, ranging from fundamental research to clinical applications. The scope of the Journal of Artificial Organs encompasses but is not restricted to blood purification, cardiovascular intervention, biomaterials, and artificial metabolic organs. Additionally, the journal will cover technical and industrial innovations. Membership in the Japanese Society for Artificial Organs is not a prerequisite for submission.